Objective: Our purpose was to investigate the clinicopathological diagnostic value of immunohistochemical antibody for insulinoma-associated protein 1 (INSM1) in biopsy specimens of SCLC. Methods: Biopsy specimens of SCLC diagnosed at the pathology department of Tangshan Gongren Hospital from January 2022 to June 2023 were selected. INSM1 expression was detected and compared with conventional neuroendocrine markers synaptophysin (SYP), chromogranin A (CHGA), and CD56 regarding expression sensitivity and specificity. Results: The sensitivity of INSM1 expression was significantly higher than that of CHGA (95% vs 50%, P = .000), but there was no statistically significant difference in the specificity of INSM1, SYP, CHGA, and CD56 expression (100% vs 94% vs 98% vs 92%, respectively, P = .241, 1.000, .126). Conclusions: INSM1 antibody shows high sensitivity and specificity in the expression of SCLC and serves as a reliable immunohistochemical marker in the clinicopathological diagnosis of SCLC in biopsy specimens.

目的 探讨Warthin瘤样黏液表皮样癌和Warthin瘤伴鳞状与黏液上皮化生的病理学特征、诊断及鉴别诊断.方法 收集1例Warthin瘤样黏液表皮样癌和1例Warthin瘤伴鳞状与黏液上皮化生病例,行免疫组化和MAML2基因检测,分析其临床病理学特征并复习相关文献.结果 War-thin瘤样黏液表皮样癌镜下观察囊内衬覆鳞状上皮和黏液柱状上皮,未发现Warthin瘤特征性的上皮细胞,伴MAML2基因重排;Warthin瘤伴鳞状与黏液上皮化生镜下可见War-thin瘤特征性的嗜酸性双层上皮,多灶衬覆鳞状上皮和黏液柱状上皮,未检测到MAML2基因重排.结论 Warthin瘤样黏液表皮样癌和Warthin瘤伴鳞状与黏液上皮化生组织学形态虽相似,但两者肿瘤性质、治疗、预后截然不同,鉴别诊断尤为重要.

艾拉光动力疗法是一种以5-氨基酮戊酸为光敏剂的靶向性药械联用技术,可通过光化学反应杀灭增生异常活跃的病变细胞,在宫颈上皮内瘤样病变及HPV感染等宫颈病变的治疗中应用广泛,虽然存在一定的光毒性风险,但在适当的治疗参数下临床疗效显著.

目的 研究不同剂量氨基酮戊酸(5-ALA)光动力对人宫颈癌Hela细胞的杀伤作用,为宫颈癌的治疗提供有价值的参考. 方法 对人宫颈癌细胞株Hela培养、传代后分为两组,观察组给予不同剂量5-ALA光动力,对照组不给予5-ALA光动力,比较两组细胞增殖抑制率、Her-2/neu表达、凋亡率情况. 结果 观察组早期凋亡率、晚期凋亡率、总凋亡率均高于对照组(P＜0.05).随着5-ALA光敏剂浓度增加,早期凋亡率、晚期凋亡率、总凋亡率也随之增加(P＜0.05).观察组Her-2/neu阳性表达率为12.5％,明显低于对照组(P＜0.05).光动力能量密度5、10、20 J/cm2细胞增殖抑制率明显大于1 J/cm2;10、20 J/cm2细胞增殖抑制率明显大于5J/cm2;光敏剂浓度1、4 mmol/L细胞增殖抑制率明显大于0.1 mmol/L(P＜0.05).光动力能量密度10、20 J/cm2细胞增殖抑制率比较,差异无统计学意义(P＞0.05);光敏剂浓度1、4 mmol/L细胞增殖抑制率比较,差异无统计学意义(P＞0.05). 结论 5-ALA光动力对人宫颈癌Hela细胞具有明显的抑制作用,还可诱导细胞凋亡,5-ALA浓度为1mmol/L,光动力能量密度10 J/cm2是最佳杀伤剂量.

Obj ective]To explore the feasibility and effectiveness of 5-aminolevulinic acid photodynamic therapy(ALA-PDT)for the treatment of cervical intraepithelial neoplasia(CIN)grade Ⅰ(CIN Ⅰ).[Methods]Totally 149 patients with CIN Ⅰ were chosen and divided into ALA-PDT treatment group(ALA group,n=38),microwave group(n=40),laser group(laser group,n=35)and freezing group(n=36).The efficacy and adverse reaction in 4 groups after treatment were assessed.[Results]After 3 months of treatment,the complete response rate in ALA group was 78.9%(30/38),which was markedly higher that in microwave group(27.5%,11/40),laser group(28.6%,10/35)and freezing group(22.2%,8/36)respectively,and there were significant differences(χ2=9.07,P <0.05).After 12 months of treatment,HPV load in ALA group was obviously lower than that in the other three groups(t=10.17,P <0.05),while HPV negative conversion rate in ALA group was significantly higher than that in the other three groups (χ2=9 .1 6 ,P <0.05).Cervical liquid based cytology showed that the abnormal number in ALA group was less than that in the other three groups,and the reverse rate of CIN Ⅰ in ALA group was obviously higher than that of the other three groups,and there was significant difference(P<0.05).The incidence rates of ulcers,infection, superficial scar in ALA group were obviously lower than those of the other three groups,and pain score in ALA group was obviously lower than in other three group(P <0.05).[Conclusion]ALA-PDT for the treat-ment of CIN I has certain efficacy with low recurrence rate,good tolerance and no obvious adverse reaction. Therefore,it is a safe and effective treatment method.

目的 探讨EphB - 2受体、HER - 2、EGFR的表达与结直肠癌生物学行为的关系.方法 采用免疫组化染色检测86例结直肠癌组织标本中EphB - 2受体、HER - 2、EGFR的表达水平,以结直肠腺瘤组织标本47例作为对照.结果 在癌旁无瘤黏膜、结直肠腺瘤和结直肠癌3组中,EphB - 2受体的表达阳性率分别为100%(86/86)、95.7%(45/47)和83.7%(72/86);HER - 2表达阳性率分别为34.9%(30/86)、42.6%%(20/47)和74.4%(64/86);EGFR表达阳性率分别为39.5%(34/86)、46.8%(22/47)和65.1%(56/86),癌旁无瘤黏膜、结直肠腺瘤与结直肠癌阳性率比较差异具有统计学意义(P＜0.05).在结直肠癌中EphB - 2受体的表达与结直肠癌的分化程度、浸润深度、淋巴结转移有关,而HER - 2、EGFR的表达与结直肠癌的浸润深度、淋巴结转移有关.结论 EphB - 2受体、HER - 2、EGFR对结直肠癌生物学行为有明显影响,可作为临床判断结直肠癌的生物学行为及预后的重要参考指标.

0 引言 本文通过研究基质溶解素(MMP-7)、微血管密度(MVD)在乳腺癌中的表达,探讨MMP-7, MVD对乳腺癌生物学特性的影响,同时分析评判MMP-7, MVD的临床实用价值.

目的探讨大肠癌中VEGF-D、VEGFR-3的表达、D2-40阳性淋巴管特点以及淋巴管生成,分析与其临床生物学行为及预后的关系。方法免疫组织化学法检测148例大肠癌VEGF-D、VEGFR-3表达及淋巴管密度（LVD）。结果大肠癌中VEGF-D、VEGFR-3在淋巴结转移组阳性率（79%、52%）高于无淋巴结转移组（61%、34%）,复发转移组阳性率（82%、52%）高于无复发转移组（59%、34%）,生存期≤3年组阳性率（81%、62%）高于生存期＞3年组（59%、35%）（均P＜0.05）;VEGF-D在淋巴管受累组阳性率（85%）高于无淋巴管受累组（60%）（P＜0.05）;LVD值在溃疡型和浸润型组中高于肿块型组,Dukes’C、D期高于DukesA、B期,淋巴结转移组高于无淋巴结转移组,淋巴管受累组高于无淋巴管受累组,复发转移组高于无复发转移组,生存期≤3年组高于生存期＞3年组（均P＜0.05）。结论大肠癌中VEGF-D、VEGFR-3表达升高与促进淋巴管生成和淋巴结转移、复发转移和预后不良有关。